Stem cell fate depends on ‘grip’

Mar. 28, 2013 The field of regenerative medicine holds great promise, propelled by greater understanding of how stem cells differentiate themselves into many of the body's different cell types. But clinical applications in the field have been slow to materialize, partially owing to difficulties in replicating the conditions these cells naturally experience.

A team of researchers from the University of Pennsylvania has generated new insight on how a stem cell's environment influences what type of cell a stem cell will become. They have shown that whether human mesenchymal stem cells turn into fat or bone cells depends partially on how well they can "grip" the material they are growing in.

The research was conducted by graduate student Sudhir Khetan and associate professor Jason Burdick, along with professor Christopher Chen, all of the School of Engineering and Applied Science's Department of Bioengineering. Others involved in the study include Murat Guvendiren, Wesley Legant and Daniel Cohen.

Their study was published in the journal Nature Materials.

Much research has been done on how stem cells grow on two-dimensional substrates, but comparatively little work has been done in three dimensions. Three-dimensional environments, or matrices, for stems cells have mostly been treated as simple scaffolding, rather than as a signal that influences the cells' development.

Burdick and his colleagues were interested in how these three-dimensional matrices impact mechanotransduction, which is how the cell takes information about its physical environment and translates that to chemical signaling.

"We're trying to understand how material signals can dictate stem cell response," Burdick said. "Rather than considering the material as an inert structure, it's really guiding stem cell fate and differentiation -- what kind of cells they will turn into."

The mesenchymal stem cells the researchers studied are found in bone marrow and can develop into several cell types: osteoblasts, which are found in bone; chondrocytes, which are found in cartilage; and adipocytes, which are found in fat.

The researchers cultured them in water-swollen polymer networks known as hydrogels, which share some similarities with the environments stem cells naturally grow in. These materials are generally soft and flexible -- contact lenses, for example, are a type of hydrogel -- but can vary in density and stiffness depending on the type and quantity of the bonds between the polymers. In this case, the researchers used covalently cross-linked gels, which contain irreversible chemical bonds.

When seeded on top of two-dimensional covalently cross-linked gels, mesenchymal stem cells spread and pulled on the material differently depending on how stiff it was. Critically, the mechanics guide cell fate, or the type of cells they differentiate it into. A softer environment would produce more fat-like cells and a stiffer environment, where the cells can pull on the gel harder, would produce more bone-like cells.

Follow this link:
Stem cell fate depends on 'grip'

Scientists criticize Italy for allowing unproven stem cell therapy

Scientists have criticized an Italian government decree allowing a group of terminally-ill patients to continue using an unproven stem cell treatment, saying such therapies may cause harm and risk exploiting desperate people.

The treatment, created by the privately-owned Stamina Foundation, was banned by Italian medicines regulator AIFA last year after it inspected their laboratories, leading to a series of legal challenges by families of patients.

In early March, Health Minister Renato Balduzzi allowed a terminally ill child to continue using the Stamina treatment after hearing the emotional pleas of her parents.

Related: Catholic Church gives its blessing to stem cell research in new book

The Health Ministry then issued an official decree on March 21 allowing 32 patients, mainly children, already using the treatment to continue it.

Scientists from around Europe released a statement on Thursday criticizing the decree, warning that Balduzzi was "riding roughshod over existing European licensing criteria", failing to protect patients from exploitation and ignoring the need for sound evidence that therapies are effective.

"These unproven and ill-prepared stem cell therapies, for which there is no scientific basis, will do nothing for patients and their families except make them poorer," said Charles French-Constant from the University of Edinburgh's Center for Regenerative Medicine.

'Dangerous precedent'

Advocates of the therapy say strict regulations work in favor of big drug companies with their portfolio of blockbuster treatments, reducing the pool of potential competitors. But scientists said Stamina's treatment was unproven and risky.

"There is no rationale for this and no evidence that these procedures are not dangerous for patients," said Professor Michele De Luca of the University of Modena.

Read the original:
Scientists criticize Italy for allowing unproven stem cell therapy

IDIBELL signs agreement with Histocell to use … – Stem Cell Cafe

Mar 28

The Bellvitge Biomedical Research Institute (IDIBELL) has signed a licensing agreement with the Spanish biotech company Histocell to make use of a patent for the treatment of acute pulmonary diseases with mesenchymal stem cells. These cells, administered intravenously, have the ability to go directly to the damaged lungs, acting as a &smart drug&.

To enhance the effect, researchers have modified this cells by genetic engineering. The studies have been developed by a team led by Josep Maria Aran, researcher at the Human Molecular Genetics group of IDIBELL, in collaboration with researchers of the Pneumology group at Vall d&Hebron Research Institute (VHIR) and the Biomedical Research Network Centre for Respiratory Diseases (CIBERES). The outcomes of the research have supposed an international patent application managed by the Technology Transfer Office (TTO) at IDIBELL.

The researchers use adult mesenchymal stem cells extracted from adipose tissue obtained from liposuction. These cells are capable of enhancing the regeneration of the damaged lung tissue and secrete inflammatory proteins therein when injected into the blood.

Improvements

The novelty patented by IDIBELL and VHIR researchers has been the insertion of improvements through genetic engineering that can significantly enhance the anti-inflammatory and regenerative power of the mesenchymal cells. Specifically, researchers have modified the antagonist to secrete interleukin 33, a regulatory protein (cytokine) that has a fundamental role in the inflammatory process.

The treatment has proven to be very effective given intravenously, although it could be considered the option of administering it by inhalation.

In the administered dose, these stem cells do not involve immune rejection, because the body removes them after their function is performed. This makes them particularly useful for treating acute diseases.

Good results

Read the original post: IDIBELL signs agreement with Histocell to use patent for acute pulmonary diseases with stem cells

Read more from the original source:
IDIBELL signs agreement with Histocell to use ... - Stem Cell Cafe

Lifespan opens stem cell research lab in Knowledge District

PROVIDENCE Lifespan opened a new stem cell research laboratory Wednesday afternoon on the fifth floor of the hospital networks Coro Building. The lab is the first phase of a major investment to turn the entire building in Providences Knowledge District into a state-of-the art research facility.

Construction of the new 11,000-sqare-foot research lab, a Center for Biomedical Research Excellence for Stem Cell Biology, was funded through a $300,000 National Institutes of Health grant to Dr. Peter Quesenberry, director of hematology oncology at Rhode Island and The Miriam hospitals.

The lab will provide researchers with the state-of-the-art technology needed to support ongoing research in the areas of cancer, tissue injury and basic stem cell biology, according to Quesenberry.

This new lab space will help us to further study the use of stem cells for the treatment of many illnesses various forms of cancer, tissue and organ damage and much more, Quesenberry said. Creating this research hub provides our researchers with the best possible resources, and places us in close proximity to the hospitals, allowing us to more appropriately collaborate with our peers, and truly bring research from the bench to the bedside.

The laboratory also will support research in novel anti-cancer treatments for pediatric and adult malignancies, and will continue to examine therapeutic mechanisms underlying refractory leukemia and lymphoma, according to hospital officials. The new lab space can accommodate 14 laboratory benches, and can accommodate 10 funded investigators, as well as their technicians and students.

Part of Rhode Island Hospitals mission is to be at the forefront of patient care by creating, applying and sharing the most advanced knowledge in health care, said Peter Snyder, senior vice president and chief of research at Lifespan. One of the ways we do that is by providing our researchers with the tools they need to conduct cutting-edge research in order to discover and create improved diagnostic measures and treatments.

This new research space is the first step in a major renovation project of the 270,000-square-foot Coro Building, creating a research facility that will serve as a focal point for clinical research in Rhode Island, according to Snyder.

Notable elected officials speaking at the labs opening and tour included Gov. Lincoln D. Chafee, Lt. Gov. Elizabeth H. Roberts, U.S. Sens. Jack Reed and Sheldon Whitehouse, U.S. Rep. James R. Langevin, and Providence Mayor Angel Taveras.

Speakers from the Rhode Island medical community included Dr. Edward Wing, dean of medicine and biological sciences at The Warren Alpert Medical School at Brown University, Dr. Timothy J. Babineau, president and CEO of Lifespan, Snyder, Quesenberry, and Dr. Louis Rice, chief of the department of medicine at Rhode Island and The Miriam hospitals.

See the rest here:
Lifespan opens stem cell research lab in Knowledge District

Hospitals performing stem cell therapy are yet to be accredited – DOH

By: Azer N. Parrocha, Philippine News Agency March 28, 2013 3:16 AM

InterAksyon.com The online news portal of TV5

MANILA, Philippines - Although guidelines for stem cell therapy in the country have already been released, the Department of Health (DOH) on Wednesday reminded the public that hospitals performing the treatment are as of the moment, not accredited.

Health Secretary Enrique Ona, in a press conference, explained that for a hospital or clinic to be considered accredited, a years worth of tests and studies have to be done to prove that the procedure is indeed safe and effective.

I hope the general public understands that these stem cells, although called innovative (form of treatment) is not standard and should not be advertised as though it is already an accepted form of treatment, Ona said.

Ona explained that the DOH still continues to look on the capacity of the treatment and will make sure that the stem cells used for procedure are accepted as protocol.

Stem cells like those coming from embryos or animals which are restricted will also be looked into by the DOH to see if there are any hospitals or clinics that do not abide by the administrative order.

If the protocol is accepted, report of results should be evaluated, he said. They are evaluated about a year to see if their claim is effective [and if it is] it will be validated.

At present, there are no hospitals or clinics completely accredited for the stem cell therapy yet. Given that, certain processes must be followed before doctors are allowed to use the treatment.

I cannot see a so-called clinic yet certifying that there is a process that is very effective, Ona explained. We have to see the type of stem cell, the type of claim they have.

Excerpt from:
Hospitals performing stem cell therapy are yet to be accredited – DOH

International Stem Cell Corporation Announces Fourth Quarter 2012 Financial Results and Provides Business Update

CARLSBAD, CA--(Marketwire - Mar 27, 2013) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company focused on therapeutic and biomedical products, today announced financial results for the three and twelve months ended December 31, 2012.

FY 2012 Highlights:

Three Months Ended December 31, 2012

Revenue for the three months ended December 31, 2012 totaled $1.25 million compared to $1.06 million for the same period in 2011. Sales for Lifeline Skin Care (LSC) and Lifeline Cell Technology (LCT) increased by 39% and 3%, respectively. LSC and LCT accounted for 48% and 52% of total revenue in the three months ended December 31, 2012.

Development expenses decreased by 8% to $3.65 million due primarily to reductions in cost of sales and consulting expenses relating to our research and development projects, partially offset by an increase in sales and marketing spending. General and administrative expenses were $1.89 million, reflecting relatively constant expense compared to the fourth quarter of 2011.

Twelve Months Ended December 31, 2012

Sales for the twelve months ended December 31, 2012 were $4.57 million compared to $4.53 million in 2011. LCT sales were $2.38 million, up 14% from 2011, representing 52% of total revenue in 2012. LSC revenues were $2.19 million compared to $2.45 million in 2011 reflecting a decrease of 11%.

Cost of sales was $1.27 million, or 28% of revenue, compared to $1.62 million or 36% of revenue in 2011. The Company successfully implemented efficiencies in its manufacturing and supply chain management for both LSC and LCT.

Net loss from development activities was $9.81 million, compared to $11.36 million in 2011 reflecting a reduction of $1.55 million or 14% primarily due to favorable reductions in cost of sales, research and development and general and administrative expenses.

Cash and cash equivalents totaled $0.65 million at December 31, 2012 compared to $1.34 million at December 31, 2011.

Excerpt from:
International Stem Cell Corporation Announces Fourth Quarter 2012 Financial Results and Provides Business Update